Abstract P2-07-29: DNADX in advanced hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer following endocrine therapy with or without palbociclib: a correlative analysis from the GEICAM/2014-12 FLIPPER phase II randomized trial | Publicación